Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;11(4):492-4.
doi: 10.1590/s1679-45082013000400015.

Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital

[Article in English, Portuguese]
Ricardo Prado Golmia, Morton Aaron Scheinberg

Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital

[Article in English, Portuguese]
Ricardo Prado Golmia et al. Einstein (Sao Paulo). 2013 Dec.

Abstract
in English, Portuguese

Objective: To compare the efficacy and the period of use of tocilizumab and infliximab during treatment of rheumatoid arthritis patients.

Methods: The period of use of two biologics with different mechanisms of action were compared in treatment of rheumatoid arthritis patients.

Res ults: Both medications showed efficacy, but the period of use with no loss of efficacy was longer in patients receiving tocilizumab when compared to infliximab.

Conclusion: Tocilizumab maintains a period of use significantly longer as compared with infliximab in patients with rheumatoid arthritis treated at a single organization.

Objetivo:: Comparar a eficácia e período de uso de tocilizumabe e infliximabe no tratamento de pacientes com artrite reumatoide.

Métodos:: Foi comparado o tempo de uso de dois biológicos com diferentes mecanismos de ação no tratamento de pacientes com artrite reumatoide.

Resultados:: Ambos os biológicos se mostraram eficazes, mas o tempo de uso sem perda de eficácia foi maior com tocilizumabe quando comparado ao infliximabe.

Conclusão:: Tocilizumabe mantém um período de uso significativamente maior do que infliximabe em pacientes com artrite reumatoide tratados em uma única instituição.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none.

References

    1. Pisetsky DS, Ward MM. Advances in the treatment of inflammatory arthritis. Best Pract Res Clin Rheumatol. 2012;26(2):251–261. - PMC - PubMed
    1. Conti F, Scrivo R, Spinelli FR, Truglia S, Magrini L, Di Franco M, et al. Outcome in patients with rheumatoid arthritis switching TNF-alpha antagonists: a single center, observational study over an 8-year period. Clin Exp Rheumatol. 2009;27(3):540–541. - PubMed
    1. Scheinberg M, Goldenberg J, Feldman DP, Nóbrega JL. Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, São Paulo, Brazil. Clin Rheumatol. 2008;27(8):1049–1052. - PubMed
    1. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33(7):901–913. - PubMed
    1. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, Swiss Clinical Quality Management Physicians Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61(5):560–568. - PubMed

MeSH terms